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Molecular analysis of BcrR, a membrane-bound bacitracin
sensor and DNA-binding protein from Enterococcus faecalis
Abstract
BcrR has been identified as a novel regulatory protein of high level bacitracin resistance encoded by the
bcrABD operon in Enterococcus faecalis. The N-terminal domain of BcrR has similarity to the
helix-turn-helix motif of DNA-binding proteins, and topological modeling predicts that the C-terminal
domain contains four transmembrane alpha-helices. These data have led to the hypothesis that BcrR
functions as both a membrane-bound sensor and transducer of bacitracin availability to regulate bcrABD
expression. To characterize the bcrABD promoter and identify the promoter elements to which BcrR
binds, a series of bcrA-lacZ fusions were constructed. A 69-bp region was identified that was essential
for bacitracin-dependent bcrA-lacZ expression. Mutations that targeted this region were used to identify
two inverted repeat sequences, each with the sequence 5'-GACA(N)(7)TGTC-3', on the bcrABD
promoter that were required for bcrA-lacZ expression. To study BcrR binding to this region, we
over-produced BcrR with a C-terminal hexa-histidine tag in Escherichia coli membranes, extracted the
protein with n-dodecyl-beta-d-maltoside, and subsequently purified it via Ni(2+)-nitrilotriacetic acid and
gel filtration chromatography to apparent homogeneity. Purified BcrR was reconstituted into liposomes,
and BcrR binding to bcrABD promoter DNA was analyzed using electrophoretic mobility shift assays.
Both inverted repeat sequences were required for BcrR binding, both in the presence and absence of
bacitracin. These data demonstrate that membrane-bound BcrR binds specifically to the bcrABD
promoter, irrespective of bacitracin concentration. We therefore propose that bacitracin-dependent
induction of bcrABD expression by BcrR occurs after DNA binding.
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BcrR has been identified as a novel 
regulatory protein of high-level bacitracin 
resistance encoded by the bcrABD operon 
in Enterococcus faecalis.  The N-terminal 
domain of BcrR has similarity to the helix-
turn-helix motif of DNA-binding proteins, 
and topological modeling predicts that the 
C-terminal domain contains four 
transmembrane α-helices.  These data have 
led to the hypothesis that BcrR functions as 
both a membrane-bound sensor and 
transducer of bacitracin availability to 
regulate bcrABD expression. To 
characterize the bcrABD promoter and 
identify the promoter elements to which 
BcrR binds, a series of bcrA-lacZ fusions 
were constructed. A 69-bp region was 
identified that was essential for bacitracin-
dependent bcrA-lacZ expression.  
Mutations that targeted this region were 
used to identify two inverted repeat 
sequences, each with the sequence 5´-
GACA(N)7TGTC-3´, on the bcrABD 
promoter that were required for bcrA-lacZ 
expression. To study BcrR binding to this 
region, we overproduced BcrR with a C-
terminal hexa-histidine tag in Escherichia 
coli membranes, extracted the protein with 
n-dodecyl-β-D-maltoside, and subsequently 
purified it via Ni2+-NTA and gel filtration 
chromatography to apparent homogeneity.  
Purified BcrR was reconstituted into 
liposomes, and BcrR binding to bcrABD 
promoter DNA was analyzed using 
electrophoretic mobility shift assays.  Both 
inverted repeat sequences were required 
for BcrR binding, both in the presence and 
absence of bacitracin. These data 
demonstrate that membrane-bound BcrR 
binds specifically to the bcrABD promoter, 
irrespective of bacitracin concentration. 
We therefore propose that bacitracin-
dependent induction of bcrABD expression 
by BcrR occurs after DNA binding.  
 
Bacitracin is a polypeptide antibiotic that 
functions by binding to and sequestering 
undecaprenyl pyrophosphate (UPP) (1).  As 
UPP acts as a carrier of peptidoglycan 
monomeric units across the cell membrane 
(2), the antibacterial nature of bacitracin 
results from its ability to block cell wall 
synthesis.  High-level bacitracin resistance in 
Enterococcus faecalis is encoded by the 
bcrABD operon that is under the control of a 
putative membrane-bound DNA-binding 
protein, BcrR (3).  In the presence of 
bacitracin, transcription of the bcrABD 
operon leads to the production of BcrA and 
BcrB, which are proposed to act as an ABC 
exporter of bacitracin, thus conferring high-
level bacitracin resistance (MIC ≥ 256 µg/ml) 
to the cell (3).  BcrD is proposed to function 
as an undecaprenyl pyrophosphate 
phosphatase that functions to increase the 
amount of UP available to the cell (3).  It has 
been demonstrated that bcrR, which is 
transcribed constitutively, is essential for 
high-level bacitracin resistance in E. faecalis 
and that transcription of bcrABD is abolished 
in the absence of bcrR (3).  The expression of 
bcrABD was found to be inducible with 
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 2 
increasing concentrations of bacitracin (3).  
The N-terminal domain (amino acid residues 
5-61) of BcrR has homology to the Xre 
family of helix-turn-helix (HTH) DNA-
binding proteins and, based on topological 
modeling, the C-terminal domain is predicted 
to contain four membrane-spanning α-helices.  
These data combined have led to the proposal 
that BcrR is a transmembrane regulatory 
protein that functions both as a sensor and 
signal transducer of bacitracin availability in 
the environment (3). 
 Regulation of bacitracin resistance in 
other bacterial genera has been exclusively 
shown to be via two-component regulatory 
systems.  These two-component systems 
regulate genes that encode putative ABC 
transporters, which, although not yet 
experimentally demonstrated, are 
hypothesized to function by pumping 
bacitracin from the cell.  In the bacitracin 
producer, Bacillus licheniformis, regulation of 
the ABC transporter (BcrABC) is via the 
BacRS two-component system (4).  Similar 
systems exist in Bacillus subtilis (5) and in 
Streptococcus mutans (6).  It has recently 
been demonstrated that the presence of both 
the putative bacitracin transporter, BceAB, 
and the two-component signal transduction 
pathway, BceRS, are required for activation 
of bceAB expression in the presence of 
bacitracin in B. subtilis (7).  These results 
indicate that the BceAB transporter interacts 
with the BceRS two-component signal 
transduction system in some manner that is 
necessary for bceAB expression (7).  
 A recent survey of prokaryotic 
genomes has revealed that one-component 
signal transduction systems, in which an input 
and output domain are fused in a single 
protein molecule, are more numerous than 
classical two-component systems (8).  This is 
the case in the genome of E. faecalis V583 
that encodes 17 two-component systems and 
158 one-component systems (9).  One such 
system is that of PrkC, which contains a 
cytoplasmic kinase output domain fused to an 
extracellular input domain via a 
transmembrane region.  This protein has been 
shown to modulate antimicrobial resistance 
and intestinal persistence, presumably in 
response to the perturbation of the cell wall 
by bile salts as detected by the extracellular 
domain (9).  The majority of one-component 
systems are thought to be cytoplasmic, as 
97% of those containing a HTH output 
domain lack transmembrane regions.  It has 
been hypothesized that, although membrane-
bound DNA-binding proteins may represent a 
more simplistic method of signal transduction 
than the classical two-component system, 
their use may be limited by restrictions in the 
ability of the protein to locate its target DNA 
(8). 
 Examples of transmembrane 
regulators are rare and include the ToxR 
family in Vibrio cholerae (10) and close 
relatives (11).  ToxR contains a single 
transmembrane α-helix separating a 
cytoplasmic DNA-binding domain from a 
short C-terminal periplasmic domain (10).  A 
role in signal transduction by ToxR may be 
likely in the presence of bile salts, where it 
regulates cholera toxin production (12) and 
expression of  the outer membrane porins 
OmpU and OmpT (13). 
 Although transmembrane regulators 
are rare, the Xre family of transcriptional 
regulators is a large family, comprised to date 
of 6002 proteins across all branches of life 
(SMART database http://smart.embl.de/) (14).  
The Xre family has been incorrectly 
annotated as the ‘xenobiotic response element 
family of transcriptional regulators’ by the 
conserved domain database (15) in NCBI.  
Rather, the Xre-like family of HTH proteins 
is named after the family member Xre, a 
repressor in the Bacillus subtilis prophage 
PBSX (16).  Although most members of the 
family remain uncharacterized, a few have 
been well characterized, including the phage 
434 (17) and lambda phage (18) repressors.  
Two members of the family in E. faecalis are 
CylR2, which functions as a repressor of 
cytolysin exotoxin production (19), and PrgX, 
which regulates conjugation in response to a 
pheromone signal (20). 
The aim of this study was to study the 
interaction of membrane-bound BcrR with the 
bacitracin resistance operon bcrABD in E. 
faecalis using an in vitro system. We show 
that membrane-bound BcrR binds to two 
inverted repeats, each with the sequence 5´-
GACA(N)7TGTC-3´, on the bcrABD 
promoter.  Both repeats are required for 
bacitracin-dependent bcrA-lacZ expression. 
 
EXPERIMENTAL PROCEDURES 
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Bacterial strains, plasmids, and growth 
conditions-The bacterial strains and plasmids 
used in this study are listed in Table 1.  E. coli 
MC1061 (21) or DH10B (22) were used for 
cloning and E. coli C41(DE3) (23) was used 
to produce BcrR containing a C-terminal 
hexa-histidine tag for purification by Ni2+-
nitrilotriacetic acid (NTA) affinity 
chromatography.  E. faecalis strains 
AR01/DGVS (3) and JH2-2 (24) were used 
for bacitracin challenge and β-galactosidase 
assays.  Plasmids used were pTrc99A (25) for 
overexpression of histidine-tagged BcrR, 
pTCVlac (26) as a transcriptional reporter and 
pAM401 (27) for the introduction of bcr 
genes into E. faecalis.   For both cloning and 
protein expression, E. coli strains were grown 
at 37 °C in 2× YT broth or on Luria-Bertani 
(LB) agar (28).  For routine growth and 
β-galactosidase assays, E. faecalis strains 
were grown at 37 °C without agitation in 
brain heart infusion (BHI) broth or on BHI 
agar.   E. coli transformants were selected on 
LB agar containing either ampicillin at 100 
µg/ml (pTrc99A), kanamycin at 50 µg/ml 
(pTCVlac) or 10 µg/ml tetracycline 
(pAM401).  E. faecalis transformants were 
selected on SR agar (29) containing 
erythromycin at 10 µg/ml (pTCVlac) or 20 
µg/ml chloramphenicol (pAM401). 
General molecular techniques-All 
molecular biology techniques were carried out 
according to standard procedures (28).  
Restriction or DNA modifying enzymes and 
other molecular biology reagents were 
obtained from Roche Diagnostics or New 
England Biolabs.  Genomic DNA of E. 
faecalis was isolated as previously described 
(30).  Transformation of E. faecalis cells 
grown in the presence of glycine was 
performed as described by Shepard and 
Gilmore (29).  All PCR were carried out with 
the Phusion™ high-fidelity PCR kit 
(Finnzymes) according to the manufacturer’s 
instructions. 
Construction of vectors for 
complementation-To introduce wild-type and 
hexa-histidine tagged bcrR into JH2-2, the 
constructs pAMBcrR and pAMBcrRHis were 
constructed, respectively.  To construct 
plasmid pAMBcrR, containing bcrR under the 
control of its own promoter, primers 
BcrRpAMf (5´-
AAATTTCCATGGTCATACAGAATTTCC
TGCAC-3´) and BcrRpAMr (5´-
AAATTTGAATTCTTATTTCATTCCCATC
TGCTT-3´) containing NcoI and EcoRI 
restriction sites (underlined), respectively, 
were used to amplify bcrR by PCR using 
AR01/DGVS genomic DNA as a template.  
The amplicon was digested with NcoI and 
EcoRI and cloned into pAM401 digested with 
the same restriction enzymes.  To construct 
plasmid pAMBcrRHis, containing C-terminal 
hexa-histidine tagged bcrR under the control 
of its own promoter, primers BcrRpAMf and 
BcrRpAMHisr (5´-
AAATTTGAATTCTTAATGATGATGATGA
TGATGTTTCATTCCCATCTGCTT-3´) 
containing NcoI and EcoRI restriction sites 
(underlined), respectively, and histidine 
codons (italicized) were used to amplify bcrR 
by PCR using AR01/DGVS genomic DNA as 
a template.  The amplicon was digested with 
NcoI and EcoRI and cloned into pAM401 
digested with the same restriction enzymes.  
These constructs were introduced into E. 
faecalis strain JH2-2 to create JH2-
2pAMBcrR and JH2-2pAMBcrRHis, 
respectively. 
Construction of bcrA-lacZ 
transcriptional fusions-To construct a series 
of bcrA-lacZ reporter fusions, primers listed 
in Table 2 were used to amplify bcrABD 
promoter DNA using plasmid pAMbcr1, 
unless otherwise stated, as a template.  
Amplified DNA was digested with the 
corresponding enzymes as indicated in Table 
2 and ligated into pTCVlac digested with the 
same enzymes.  All promoter regions 
amplified by PCR were confirmed by DNA 
sequencing.  To map the bcrABD promoter, a 
series of promoter-lacZ fusions were created 
as shown in Figure 1.  To create plasmids 
pTCVA, pTCVB, pTCVC, pTCVD, and 
pTCVE the forward primers EfbcrAP2F, 
EfbcrAP7F, EfbcrAP6F, EfbcrAP5F, and 
EfbcrAP3F were used, respectively, with the 
reverse primer EfbcrAP2R. 
 In order to identify DNA motifs 
important for BcrR binding in the bcrABD 
promoter, a series of nucleotide substitutions 
were introduced by PCR overlap extension 
(31) into the same 389-bp bcrABD promoter 
sequence used to create plasmid pTCVA.  
The mutated PCR product was then cloned 
into pTCVlac and sequenced to ensure 
fidelity of the PCR reaction.  To create 
pTCVA1, two pairs of primers (viz. 
EfbcrAP2EcoF with BcrAarea4R and 
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 4 
BcrAarea4F with EfbcrAP2R) and pAMbcr1 
template were used to generate mutated DNA 
fragments.  These overlapping fragments 
were then used for overlap extension PCR 
with the external primers EfbcrAP2EcoF and 
EfbcrAP2R (Table 2).  To create pTCVA2, 
pTCVA3, pTCVA4, pTCVA1+3, and 
pTCVA2+4 the same procedure as above was 
followed using the internal primers given in 
Table 2, with the exception of pTCVA1+3 
and pTCVA2+4 where plasmids pTCVA3 
and pTCVA2 served as template, 
respectively. 
Bacitracin challenge and β-
galactosidase assays-E. faecalis containing 
bcrABD-promoter reporter constructs in 
pTCVlac were grown to an OD600 of 
approximately 0.5.  Cells were separated into 
10 ml aliquots and 256 µg/ml of bacitracin 
added unless otherwise stated.  Following 1 h 
incubation at 37 °C, cells were harvested, 
rapidly frozen, and stored at -20 °C.  The β-
galactosidase activity of cells was determined 
as described previously (32). 
Mapping of the transcriptional start site 
(TSS) of bcrABD-The TSS of bcrABD was 
mapped by 5'-RACE (rapid amplification of 
cDNA ends) using the components of the 
3'/5'-RACE kit (Roche) according to the 
manufacturer’s instruction.  RNA was 
isolated from E. faecalis AR01/DGVS grown 
in the presence of 256 µg/ml bacitracin.  First 
strand cDNA was synthesised from 4.8 µg 
total RNA with the bcrA-specific primer 
bcrA-RACE1 (5´-
GAGTAATCGGAAAAGACCT-3´). The 
resulting cDNA was purified and dA-tailed 
following the kit instructions. Purified dA-
tailed cDNA was then used as a template for 
PCR using the Oligo dT-anchor primer and 
bcrA-specific primer bcrA-RACE2 (5´-
CTACTCCACTTTTAGATAC-3´). The 
resulting PCR product was gel purified and 
used as template for a second PCR using the 
PCR anchor primer and nested bcrA-specific 
primer bcrA-RACE3 (5´-
CTCATACCCTGTTAAATTACTG-3´). This 
PCR product was then sequenced using 
primer bcrA-RACE3.  
Construction of vectors for over-
expression of BcrR-Two constructs for the 
expression of recombinant BcrR were created 
using the expression vector pTrc99A.  To 
construct plasmid pTrcBcrR, for the 
expression of BcrR, primers BcrRFwd (5´-
AAATTTCCATGGAATTTAATGAAAAGC
TACAA-3´) and BcrRRev (5´-
AAATTTGTCGACTTATTTCATTCCCATC
TGCTT-3´) containing NcoI and SalI 
restriction sites (underlined), respectively, 
were used to amplify bcrR by PCR using 
AR01/DGVS genomic DNA as a template.  
The amplicon was digested with NcoI and 
SalI and cloned into pTrc99A digested with 
the same restriction enzymes.  To construct 
plasmid pTrcBcrRHis, for the expression of 
BcrR containing a hexa-histidine tag at the C-
terminus (corresponding to italicized 
nucleotides), primers BcrRFwd and 
HisBcrRRev (5´-
AATTTGTCGACTTAGTGGTGGTGGTGG
TGGTGTTTCATTCCCATCTGCTT-3´), 
containing a SalI site (underlined), were used 
to amplify bcrR by PCR.  The amplicon was 
digested with NcoI and SalI and cloned into 
pTrc99A digested with the same restriction 
enzymes.  All regions amplified by PCR were 
verified by DNA sequencing. 
Expression and purification of hexa-
histidine tagged BcrR-Plasmid pTrcBcrRHis 
was electroporated into E. coli C41(DE3) 
prior to expression trials.  Following 
inoculation with an overnight culture (0.1%), 
a 15-l culture was grown in 2 × YΤ medium 
supplemented with 100 µg/ml ampicillin in a 
fermenter (Bioflo 410, New Brunswick 
Scientific) with agitation (200 rpm) and 
aeration (12 l/min) at 37 °C.  At an OD600 of 
0.7, the culture was induced with 1 mM 
isopropyl-β-D-thiogalactopyranoside (IPTG) 
and incubated for a further 2 h.  Cells were 
harvested by centrifugation at 9,220 × g for 
10 min.  Cells were washed once in 20 mM 
sodium phosphate buffer (pH 7.4), 
resuspended in 20 mM sodium phosphate 
buffer (pH 7.4) with 0.1 mM 
phenylmethylsulfonyl fluoride (PMSF), and 
disrupted by three passages through a French 
pressure cell (American Instrument 
Company) at 20,000 psi.  DNaseI was added 
(0.1 mg/ml) and the suspension incubated on 
ice for 1 h.  Unbroken cells were removed by 
centrifugation at 8,000 × g for 10 min and the 
membranes collected from the cell-free 
supernatant by ultracentrifugation at 
180,000 × g for 50 min.  The membranes 
were washed once in 20 mM sodium 
phosphate buffer (pH 7.4) containing 0.1 mM 
PMSF and 5 mM DL-dithiothreitol (DTT), 
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 5 
and stored at -70 °C until use.  Prior to 
solubilization, membranes were washed in 
buffer A (20 mM sodium phosphate, pH 7.4, 
500 mM NaCl, 0.1 mM PMSF, 5 mM DTT, 
10% glycerol) containing 1% sodium cholate.  
The membranes were then solubilized in 
buffer A containing 20 mM imidazole and 
1% n-dodecyl-β-D-maltoside (DDM) with 
gentle stirring at room temperature for 1 h at a 
membrane protein concentration of 
approximately 5 mg/ml.  The mixture was 
ultracentrifuged at 180,000 × g for 50 min.  
The supernatant (solubilized BcrR) was then 
loaded in two batches onto a 1-ml HisTrap™ 
HP Ni2+-NTA-sepharose column (Amersham 
Biosciences) pre-equilibrated with buffer A 
containing 20 mM imidazole and 0.05% 
DDM.  The protein was eluted with a step-
wise gradient of buffer B (buffer A with 500 
mM imidazole and 0.05% DDM).  Fractions 
containing BcrR were pooled and 
concentrated using an Amicon® centrifugal 
filter with a 10,000 molecular weight cutoff.  
Concentrated protein (approx. 2 mg) was 
loaded in 0.5 ml fractions onto a Superose 6 
(10/300) GL column (Amersham 
Biosciences) for further purification by gel 
filtration and eluted in buffer C (20 mM 
HEPES, pH 7.0, 150 mM NaCl, 0.1 mM 
PMSF, 5 mM DTT, 10% glycerol, 0.025% 
DDM) at a flow rate of 0.5 ml/min. 
General biochemical techniques-Protein 
concentrations of membrane fractions were 
determined by the BCA method (Pierce) 
using bovine serum albumin (BSA) as a 
standard.  Protein concentrations of purified 
BcrR and proteoliposomes were estimated by 
comparison to BSA standards separated by 
sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) or by Bradford 
assay (33).  Protein samples (15-20 µg, unless 
otherwise stated) were routinely separated by 
14% SDS-PAGE using the buffer system 
described by Laemmli (34).  Protein was 
visualized by staining with Simply Blue Safe 
Stain (Invitrogen). 
Western Blotting-Samples separated by 
SDS-PAGE were transferred to a 
polyvinylidene fluoride (PVDF) membrane 
by electroblotting using a Mini Trans-Blot® 
electrophoretic transfer cell (Bio-Rad) 
according to the manufacturer’s instructions.  
Histidine-tagged BcrR was detected by 
incubation with Anti-His HRP conjugate 
(Qiagen) according to the manufacturer’s 
instructions.  The antibody-specific bands 
were visualized using the SuperSignal® West 
Pico chemiluminescence system (Pierce). 
Reconstitution of purified BcrR into 
liposomes-A 50 mg/ml suspension of either 
phosphatidylcholine or E. coli total lipid 
extract (Avanti Polar Lipids, Inc.) was 
produced by vortexing the lipid in 
proteoliposome buffer (10 mM HEPES, pH 
7.0, 1 mM MgCl2, 5 mM DTT).  To prepare 
the lipids for reconstitution, the suspension 
was sonicated twice for 30 s on ice with a 
microtip sonicator at an output of 40 W and 
cooled on ice for 1 h.  Purified BcrR was 
added to the suspension to obtain a lipid-to-
protein ratio of 50:1 (w/w).  In some instances 
Zn2+-bacitracin was also added at a ten-fold 
molar excess to BcrR (0.33 mM).  Triton X-
100 was added to a final concentration of 
0.3% (w/v) and the mixture was incubated at 
room temperature with gentle stirring for 20 
min.  Aliquots of 50 mg, 50 mg, and 80 mg 
Bio-Beads® (Bio-Rad) were added 
consecutively, each time removing the 
exhausted Bio-Beads®, and incubated at room 
temperature with gentle stirring for 45 min 
each.  The proteoliposomes were collected by 
ultracentrifugation at 180,000 × g for 50 min 
and the pellet resuspended in proteoliposome 
buffer.  BcrR incorporation into liposomes 
was estimated by SDS-PAGE analysis to be 
90% by comparing supernatant and pellet 
fractions.  Proteoliposomes were either used 
immediately or stored at 4 °C for not more 
than 48 h prior to use in electrophoretic 
mobility shift assays. 
Preparation of DNA probes for 
electrophoretic mobility shift assay-DNA 
probes for electrophoretic mobility shift assay 
were generated by PCR.  A 116-bp PCR 
product, encompassing the putative BcrR 
DNA-binding sites, designated Bind1, was 
generated using primers EfbcrAP7F (5´-
AACATCGAATTCCCTTGAAAATAGGCT
CTGAC-3´) and EfbcrAP7R (5´-
CACATAGGATCCGCCAAGAAACCTAC
CGTCAC-3´), respectively, and plasmid 
pAMbcr1 as template.  A 184-bp PCR 
product, encompassing the mutated BcrR 
DNA-binding sites, designated Bind2, was 
generated using primers EfbcrAP2EcoF, and 
EfbcrAP7R with plasmid pTCVA1+3 as 
template.  A PCR product, encompassing 116 
bp of the bcrA coding region, designated 
bcrA116 was generated using primers 
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 6 
BcrA116F (5´-
TGAACCGATTAACGGGCTTG-3´) and 
BcrA116R (5´-
TCGCTTAAAACATGGCTTGA-3´) and 
plasmid pAMbcr1 as template.  In instances 
where the PCR product was radioactively-
labeled, PCR was conducted in the presence 
of 5 mM dNTPs and 0.13 µM (20 µCi) [α-
32P]dCTP (Amersham Biosciences).  PCR 
products were purified using a High Pure 
PCR Product Purification kit (Roche).  The 
concentration of unlabeled PCR products was 
determined by spectrophotometry and the 
concentration of labeled PCR products was 
determined by gel electrophoresis with 
unlabeled DNA of a known concentration. 
Electrophoretic mobility shift assay-
Binding reactions were performed in a total 
volume of 10 µl of binding buffer (10 mM 
HEPES, pH 7.5, 4% glycerol, 0.5 mM EDTA, 
1 mM MgCl2, 0.5 mM DTT, 50 mM NaCl, 
0.5 µg poly(dI-dC)).  Different amounts of 
proteoliposomes containing BcrR were 
incubated with binding buffer at room 
temperature for 10 min prior to the addition of 
1.2 ng of labeled DNA and different amounts 
of unlabeled DNA.  Following incubation for 
20 min at room temperature, 1 µl of loading 
dye (90 mM Tris base, 90 mM boric acid, 2 
mM Ficoll 400, 1% bromophenol blue (w/v)) 
was added and the mixture was loaded onto a 
6% native acrylamide gel (37.5:1 
acrylamide:bis-acrylamide) that had 
previously been run for 5 min at 300 V.  
Electrophoresis took place in pre-cooled 0.5 × 
TBE (44.5 mM Tris base, 44.5 mM 
orthoborate, 1 mM EDTA) at 300 V for 18 
min.  The gel was sealed in plastic and 
exposed to X-ray film (Agfa) for 18 – 48 h.  
Electrophoretic mobility shift assays in the 
presence of Zn2+-bacitracin were performed as 
described above, but with EDTA excluded 
from all buffers. 
 
RESULTS AND DISCUSSION 
 
Activation of bcrA-lacZ expression by 
bacitracin-To investigate the activation of 
bcrA-lacZ expression by bacitracin and the 
potential influence of bcrAB on this 
expression, we created the bcrA-lacZ 
transcriptional reporter, pTCVA.  A PCR 
product encompassing the -219 to +170 
region relative to the bcrA start codon was 
cloned upstream of the promoterless lacZ 
gene in pTCVlac to create pTCVA (bcrA-
lacZ) (Fig. 2).  E. faecalis strains were 
transformed with pTCVA and the expression 
of bcrA-lacZ studied.  When strain 
AR01/DGVSpTCVA, containing the bcr 
locus, was challenged with bacitracin, 
expression of bcrA-lacZ increased with 
increasing bacitracin concentration (Fig. 1A). 
Maximal levels of bcrA-lacZ expression were 
achieved at 256 µg/ml bacitracin.  No 
induction of bcrA-lacZ was observed in the 
absence of bacitracin (ie. < 1 Miller unit).  
These results show an identical pattern of 
bacitracin-dependent bcrABD expression to 
that reported for bcrABD expression obtained 
by Northern blot analysis (3).  Importantly, 
the data demonstrate that the promoter region 
used for the bcrA-lacZ construct in pTCVA 
contains the critical regulatory sequences 
necessary for bacitracin-dependent 
expression. 
To investigate if bcrAB had a role in 
the activation of bcrA-lacZ expression by 
bacitracin in a similar manner to that 
described for bceAB in B. subtilis (7), a two-
plasmid system was established in the 
bacitracin-sensitive E. faecalis strain, JH2-2.  
The transcriptional reporter, pTCVA was 
introduced into JH2-2 along with either bcrR 
alone, as harbored on pAMBcrR, or with both 
bcrR and bcrAB, as harbored on pAMbcr3 
(3).  When cells were challenged with 
bacitracin, expression of bcrA-lacZ increased 
with increasing bacitracin concentration 
(Figures 1B and C) in a similar pattern to that 
observed previously (Fig 1A). However, the 
sensitivity of the system was strongly 
influenced by the presence of bcrAB.  
Maximal levels of bcrA-lacZ expression were 
achieved at 256 µg/ml bacitracin in the 
presence of bcrAB (Fig. 1B) and at only ≥ 0.5 
µg/ml bacitracin in the absence of bcrAB (Fig. 
1C).  In all instances, no induction of bcrA-
lacZ was observed in the absence of 
bacitracin (ie. < 1 Miller unit), nor was 
induction of bcrA-lacZ expression observed in 
JH2-2 in the absence of bcrR at any of the 
bacitracin concentrations tested (data not 
shown). 
As we observed bcrA-lacZ expression 
in either the presence or absence of BcrAB, 
we conclude that BcrAB is not required for 
activitation of transcription of bcrABD in E. 
faecalis.  Although this observation differs 
from that in B. subtilis, where bceAB is 
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required for bceAB expression (7), it is 
unsurprising, as the putative transporters 
BcrAB and BceAB of E. faecalis and B. 
subtilis, respectively, belong to different 
families within the ABC transporter class (7).  
We propose that the activation of bcrA-lacZ 
expression at lower bacitracin concentrations 
in the absence of bcrAB (0.5 µg/ml compared 
to 256 µg/ml) is due to the absence of the 
function of the BcrAB transporter.  In the 
absence of BcrAB, the bacitracin-related 
stimulus is not removed from BcrR and the 
system is saturated at lower bacitracin 
concentrations.  The observation that bcrA-
lacZ expression can be activated by as little as 
0.5 µg/ml bacitracin indicates that activation 
of bcrA-lacZ expression is not due to the 
antibacterial activity of bacitracin, as at this 
concentration bacitracin is likely to have no 
effect on this strain with an MIC to bacitracin 
of 32 µg/ml.  Rather, we propose that BcrR is 
highly sensitive to bacitracin either directly, 
or via an intermediate such as UPP.  In 
accordance with this proposal, challenge of 
AR01/DGVSpTCVA with a range of other 
cell wall-active antimicrobial compounds was 
unable to induce bcrA-lacZ expression, 
indicating that BcrR does not sense cell wall 
stress or a build up of cell wall precursors 
(data not shown). 
Mapping of the bcrABD promoter-To 
elucidate the interaction of BcrR with the 
bcrABD promoter region, we set out to 
identify the regulatory DNA elements 
required for BcrR binding and activation of 
bcrABD transcription.  A series of bcrA-lacZ 
fusions that progressively truncated the 
intergenic region between bcrR and bcrABD 
was constructed (Fig. 2).  E. faecalis strain 
AR01/DGVS was transformed with these 
constructs and the induction of bcrA-lacZ 
expression in response to bacitracin studied 
(Fig. 2).  As the promoter of bcrABD was 
progressively truncated, we observed no 
significant change in the induction of bcrA-
lacZ by bacitracin until we reached 133 bp 
upstream of the bcrA start codon (Fig. 2).  We 
determined that a 69-bp region (-152 to -83) 
was essential for maximum induction of 
bcrA-lacZ expression.  The ability of BcrR to 
induce bcrA-lacZ expression was impaired in 
constructs containing only a partial segment 
of this region (i.e. pTCVC and pTCVD) and 
was abolished in a construct (i.e. pTCVE) 
completely lacking this region (Fig. 2). 
DNA sequence analysis of the 69-bp 
region revealed two inverted repeat regions 
separated by 15 nucleotides with the sequence 
5´-GACA(N)7TGTC-3´ (Fig. 3).  To 
determine the significance of the inverted 
repeats within the bcrABD promoter, PCR 
overlap extension was used to introduce 
mutations in the repeats using the full-length 
promoter construct pTCVA (Fig. 3).  These 
mutated bcrA-lacZ promoter constructs were 
electroporated into strain AR01/DGVS and 
the induction of bcrA-lacZ expression in 
response to bacitracin was studied (Fig. 3).  
Mutation of 5´-CTGACA-3´ to 5´-CCCCCA-
3´ in regions R1 and R3 (Fig. 3) resulted in 
induction of bcrA-lacZ expression by 
bacitracin at approximately only 13% and 
20% of wild-type activity, respectively.  
Mutation of 5´-GTGTC-3´ to 5´-GAAAA-3´ 
in regions R2 and R4 resulted in only 6% and 
61% of wild-type bcrA-lacZ expression 
levels, respectively.  To determine the effect 
of mutating both inverted repeats, mutations 
were introduced in regions R1 and R3 
simultaneously and also regions R2 and R4 
simultaneously.  Both of these mutated 
regions completely abolished expression of 
bcrA-lacZ (Fig. 3), indicating that the 
presence of the inverted repeats was essential 
for induction of bcrA-lacZ expression by 
BcrR in the presence of bacitracin.  No 
significant bcrA-lacZ expression was 
observed in any of the mutant constructs in 
the absence of bacitracin (data not shown).  
Mutations made within the 69-bp region that 
fell outside of the inverted repeat sequences 
had no effect on the induction of bcrA-lacZ 
expression by bacitracin (data not shown). 
 Based on the finding that the inverted 
repeats are essential for the induction of bcrA-
lacZ expression in response to bacitracin, we 
propose that they may constitute the BcrR 
recognition sequence for BcrR binding to the 
bcrABD promoter.  To test this hypothesis, we 
conducted electrophoretic mobility shift 
assays with bcrABD promoter DNA, as 
described below. 
To determine the start site for 
bcrABD transcription, the 5´-end of the 
bcrABD transcript from AR01/DGVS grown 
in 256 µg/ml bacitracin was identified by 5´-
RACE analysis (Fig. 4).  Putative -10 and -35 
elements were also identified.   The inverted 
repeats proposed to function as BcrR-binding 
sites were located upstream of these elements 
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 8 
(centered around -81), consistent with BcrR 
functioning as an activator (Fig. 4). 
Expression of BcrR in E. faecalis and E. 
coli-To study membrane-bound DNA-binding 
proteins, DNA binding assays have been 
either performed with inverted membrane 
vesicles that may contain other potentially 
contaminating proteins (10, 35), soluble 
variants of the protein(36, 37), in the presence 
of detergent (38), or by reconstitution of 
purified protein into liposomes (39).  The 
level of bcrR expression in native membranes 
of E. faecalis was too low for electrophoretic 
mobility shift assays with bcrABD promoter 
DNA (data not shown).  Therefore, we 
developed a recombinant method to 
overproduce BcrR in E. coli.  Initial 
experiments utilized the expression vector 
pTrc99A harboring bcrR with no affinity tags 
(i.e. pTrcBcrR).  IPTG induction of E. coli 
C41(DE3) containing plasmid pTrcBcrR 
inhibited E. coli growth when compared to 
the uninduced control or E. coli containing 
pTrc99A, suggesting that bcrR expression in 
E. coli was toxic (data not shown).  SDS-
PAGE analysis of the membrane fraction of 
this strain revealed the presence of an 
additional protein band at a molecular weight 
of approximately 20 kDa (Fig. 5A, lane 3) 
that was absent in the empty vector control 
(Fig. 5A, lane 2).  N-terminal sequencing by 
Edman degradation of the overproduced 
protein confirmed that the first ten N-terminal 
amino acids were identical to the predicted 
BcrR N-terminal protein sequence 
(MEFNEKLQQL).  No BcrR was found in 
the soluble fraction, confirming the predicted 
membrane localization of BcrR, even in E. 
coli (data not shown).  Electrophoretic 
mobility shift assays conducted with E. coli 
inverted membrane vesicles in which BcrR 
had been overproduced, yielded inconsistent 
results (data not shown). 
Purification of BcrR-To further facilitate 
electrophoretic mobility shift assays, we 
purified BcrR using affinity chromatography.  
A hexa-histidine tag was introduced at the C-
terminus of BcrR, to create plasmid 
pTrcBcrRHis.  The addition of the histidine 
tag had no significant effect on the function of 
BcrR, as we observed no significant 
difference in the activation of bcrA-lacZ 
expression by bacitracin in JH2-2pTCVA in 
either the presence of wild-type (pAMBcrR), 
or hexa-histidine tagged BcrR (pAMBcrRHis) 
(data not shown).  When pTrcBcrRHis was 
expressed in E. coli C41(DE3), a dominant 
membrane associated band, with an 
approximate molecular weight of 21 kDa, 
became apparent by SDS-PAGE analysis 
(Fig. 5A, lane 4).  Probing His-tagged 
proteins in the membrane fraction with an 
anti-His antibody by Western blot analysis 
demonstrated that this overproduced band 
contained a histidine tag and was indeed His-
tagged BcrR (BcrRHis) (data not shown). 
 BcrRHis was extracted from inverted 
membrane vesicles of E. coli using 1% DDM 
(Fig. 5B, lane 4).  Other detergents such as 
Triton X-100, n-octylglucoside, or sodium 
dodecylsulfate were less effective in 
extracting BcrRHis from E. coli membranes 
(data not shown).  A 1% sodium cholate wash 
of the inverted membrane vesicles was 
included prior to extraction with DDM, as it 
was found to remove contaminating proteins, 
but did not extract BcrRHis (Fig. 5B, lane 6).  
Solubilized BcrRHis was bound to a Ni2+-NTA 
column and eluted in 300 mM imidazole (Fig. 
5C, lane 2).  BcrRHis was further purified by 
gel filtration (Fig. 5C, lane 3).  Gel-filtration 
resulted in the elution of three peaks possibly 
corresponding to monomer, dimer and 
aggregated states of the protein, with the 
monomer predominating (data not shown).  
The purity was estimated to be greater than 
95% by SDS-PAGE (Fig. 5C).  BcrRHis 
displayed an intrinsic ability to dimerize, as a 
second fainter band that also associated with 
the anti-His antibody in Western Blot analysis 
was consistently observed running at 
approximately twice the molecular weight of 
BcrR in SDS-PAGE (data not shown). 
BcrR binds to the bcrABD promoter and 
recognizes inverted repeats-In order to study 
the DNA-binding function of BcrR, we 
attempted to use BcrRHis in DDM and BcrRHis 
reconstituted into liposomes (DDM removed) 
for electrophoretic mobility shift assays with 
the bcrABD promoter region. BcrRHis was 
reconstituted using Triton X-100 treated 
liposomes and removal of the detergent with 
Bio-Beads®.  After harvesting the 
proteoliposomes by high-speed 
centrifugation, > 90% of BcrRHis had been 
reconstituted into the liposomes (Fig. 5D, 
lane 3), and only trace amounts of BcrRHis 
were found in the supernatant fraction (non-
incorporated) (Fig. 5D, lane 2).  The protocol 
used here is known to favor insertion of 
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proteins with the hydrophilic portion 
protruding outwards (40), but some BcrRHis 
molecules will be in the opposite orientation, 
unable to bind DNA. 
 A 116-bp [32P]-labeled DNA 
fragment, designated Bind1, encompassing 
the 69-bp region required for expression of 
bcrA-lacZ activity and containing the 
BcrR-binding sites was used as a DNA probe 
for BcrRHis binding.  In addition, a 184-bp 
[32P]-labeled DNA fragment, designated 
Bind2, in which the inverted repeats had been 
mutated in regions R1 and R3, was also 
obtained. Despite numerous attempts, no 
specific retardation of bcrABD promoter 
DNA could be observed with BcrRHis in DDM 
(data not shown).  In the presence of 
proteoliposomes containing BcrRHis, Bind1 
displayed a mobility shift at approximate 
molar ratios of 2000:1 protein:DNA and 
above (Fig. 6A, lanes 2-5).  We hypothesize 
that a large excess of protein is required to 
induce a mobility-shift due to a number of 
factors.  These include a low ratio of protein-
to-lipid in the proteoliposomes, BcrRHis 
orientated in the opposite direction with the 
DNA-binding domain on the inside of the 
proteoliposomes, and potential clumping of 
proteoliposomes preventing BcrRHis from 
accessing target DNA.  Previously described 
electrophoretic mobility shift assays with 
proteoliposomes have also required large 
quantities of protein to DNA for similar 
reasons (39). 
 In contrast to results obtained using 
Bind1, Bind2 containing the inverted repeats 
mutated at regions R1 and R3, displayed no 
mobility shift in the presence of 
proteoliposomes containing BcrRHis at similar 
molar protein:DNA ratios (Fig. 6A, lanes 7-
10).  This indicated that the inverted repeats 
within the putative BcrR binding domains are 
necessary for BcrR recognition and binding of 
bcrABD promoter DNA.  These data 
corroborate our expression data, where the 
region encompassed by Bind1 is necessary for 
full induction of bcrA-lacZ activity and the 
mutations contained in Bind2 abolish bcrA-
lacZ expression. 
 To investigate the specificity of BcrR 
binding to Bind1, we amplified a 116-bp 
fragment of the bcrA coding region by PCR to 
produce bcrA116.  Addition of unlabeled 
bcrA116, and also unlabeled Bind2, in both 
50 and 100-fold excess to [32P]-labeled Bind1 
did not influence the ability of BcrRHis to shift 
Bind1 (Fig. 6B, lanes 5-6 and lanes 9-10).  In 
contrast, addition of both 50 and 100-fold 
excess unlabeled Bind1 completely abolished 
the ability of BcrRHis to shift [32P]-labeled 
Bind1 (Fig. 6B, lanes 7-8).  These results 
indicate that complex formation between 
BcrRHis and Bind1 is a specific interaction and 
that the ability of BcrR to bind DNA is 
dependent on the presence of functional BcrR 
binding sites within the DNA sequence. 
 As bacitracin is the inducer of BcrR, 
we reasoned that the addition of bacitracin in 
electrophoretic mobility shift assays may have 
an effect on the interaction of BcrR with 
bcrABD promoter DNA.  To test this 
hypothesis, we conducted electrophoretic 
mobility shift assays with proteoliposomes 
containing BcrRHis that had been formed in 
both the presence and absence of bacitracin, 
at ten-fold molar excess to BcrRHis, in the 
reaction mixture.  Under all conditions, using 
[32P]-labeled Bind1 as a DNA probe, we did 
not observe any difference in the shift or the 
amount of protein required to induce a shift of 
DNA as compared to proteoliposomes 
prepared in the absence of bacitracin (data not 
shown).  We assumed that because bacitracin 
binds to UPP in lipid membranes, the 
presence of UPP may be necessary in the 
liposomes in order for bacitracin to influence 
the BcrR-DNA interaction.  All experiments 
were therefore repeated with proteoliposomes 
containing total E. coli lipids.  No significant 
difference in BcrRHis-DNA interactions were 
observed between proteoliposomes made with 
total E. coli lipids and those made with 
phosphatidylcholine, suggesting UPP from E. 
coli had no effect on BcrRHis binding to DNA 
(data not shown).  We hypothesized that no 
change in BcrRHis-DNA interaction was 
observed in the presence of bacitracin, either 
because the mechanism of induction by 
bacitracin is more complex than this 
experimental system will allow, or the nature 
of DNA-binding is altered in a manner that is 
not detectable by electrophoretic mobility 
shift assay, such as a shift of BcrR on the 
DNA without a significant alteration in 
affinity. 
 It has been hypothesized that the 
number of membrane-bound transcriptional 
activator proteins must be limited due to 
difficulties encountered by the protein in 
locating a specific DNA target (8).  BcrRHis 
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was able to specifically bind bcrABD 
promoter DNA in the absence of the inducer 
bacitracin. These data may suggest that 
membrane-bound BcrR overcomes the need 
to locate its specific DNA target in the 
presence of bacitracin by simply remaining 
bound to the DNA and undergoing a 
conformational shift on the bcrABD promoter 
upon bacitracin binding.  In this regard, BcrR 
shows some similarities with the CylR1 and 
CylR2 complex of E. faecalis (19, 41).  
CylR1 is a predicted membrane protein with 
no homologues of known function that acts in 
concert with CylR2, a cytoplasmic protein 
that contains a XRE family HTH domain, to 
repress transcription of cytolysin genes.  As 
both CylR1 and CylR2 are required for 
repression, it has been proposed that CylR1 
and CylR2 form a complex (19).  This 
complex could potentially represent a system 
that, like BcrR, functions to transmit a signal 
through the membrane without phosphorelay.  
The CylR2 repressor binds as a dimer to an 
inverted repeat within the cytolysin promoter 
(41).  Structure modeling of CylR2 binding to 
this repeat predicts that the protein binds with 
dyad symmetry to two adjacent major grooves 
on the DNA.  The sequence to which CylR2 
is thought to bind is strikingly similar to the 
sequence of the inverted repeats identified for 
BcrR binding.  The CylR2 subunit binding to 
the inverse DNA strand is predicted to bind to 
T1, G3,A4,C5 of the sequence 5´-TTGACA-3´ 
found on the cytolysin promoter (41).  By 
comparison, the upstream sequence of both 
inverted repeats for BcrR-binding is 5´-
ctGACA-3´.  It has been proposed that the 
presence of inducer causes a shift in the 
footprint of CylR2 on the promoter (41).  We 
observed that bacitracin had no effect on the 
mobility-shift of bcrABD promoter DNA.  We 
propose, therefore, that BcrR binds as a dimer 
at each inverted repeat sequence on the 
bcrABD promoter irrespective of bacitracin 
concentration and that activation of bcrABD 
expression occurs post DNA binding of BcrR. 
Further study is required to gain additional 
insight into the mechanism of bcrABD 
transcriptional activation. 
 
Acknowledgements-This work and S.G. were 
supported by a Marsden Grant from the Royal 
Society of New Zealand.  J.C.G. was 
supported by an Otago Postgraduate 
Scholarship from the University of Otago, the 
Todd Foundation Award for Excellence and 
the William Georgetti Scholarship from the 
New Zealand Vice Chancellor’s Committee. 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
 11 
 
REFERENCES 
1. Stone, K. J., and Strominger, J. L. (1971) Proc. Natl. Acad. Sci. U. S. A. 68, 3223-3227 
2. Anderson, J. S., Matsuhashi, M., Haskin, M. A., and Strominger, J. L. (1965) Proc. Natl. Acad. Sci. U. S. 
A. 53, 881-889 
3. Manson, J. M., Keis, S., Smith, J. M., and Cook, G. M. (2004) Antimicrob. Agents. Chemother. 48, 3743-
3748 
4. Neumüller, A. M., Konz, D., and Marahiel, M. A. (2001) Eur. J. Biochem. 268, 3180-3189 
5. Ohki, R., Giyanto, Tateno, K., Masuyama, W., Moriya, S., Kobayashi, K., and Ogasawara, N. (2003) 
Mol. Microbiol. 49, 1135-1144 
6. Tsuda, H., Yamashita, Y., Shibata, Y., Nakano, Y., and Koga, T. (2002) Antimicrob. Agents Chemother. 
46, 3756-3764 
7. Bernard, R., Guiseppi, A., Chippaux, M., Foglino, M., and Denizot, F. (2007) J. Bacteriol. Epub ahead 
of print 
8. Ulrich, L. E., Koonin, E. V., and Zhulin, I. B. (2005) TRENDS Microbiol. 13, 52-56 
9. Kristich, C. J., Wells, C. L., and Dunny, G. M. (2007) Proc. Natl. Acad. Sci. U. S. A. 104, 3508-3513 
10. Miller, V. L., Taylor, R. K., and Mekalanos, J. J. (1987) Cell 48, 271-279 
11. Osorio, C. R., and Klose, K. E. (2000) J. Bacteriol. 182, 526-528 
12. Hung, D. T., and Mekalanos, J. J. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 3028-3033 
13. Provenzano, D., Schuhmacher, D. A., Barker, J. L., and Klose, K. E. (2000) Infect. Immun. 68, 1491-
1497 
14. Letunic, I., Copley, R. R., Pils, B., Pinkert, S., Schultz, J., and Bork, P. (2006) Nucleic Acids Res. 34, 
D257-260 
15. Marchler-Bauer, A., Anderson, J. B., Derbyshire, M. K., DeWeese-Scott, C., Gonzales, N. R., Gwadz, 
M., Hao, L., He, S., Hurwitz, D. I., Jackson, J. D., Ke, Z., Krylov, D., Lanczycki, C. J., Liebert, C. A., 
Liu, C., Lu, F., Lu, S., Marchler, G. H., Mullokandov, M., Song, J. S., Thanki, N., Yamashita, R. A., Yin, 
J. J., Zhang, D., and Bryant, S. H. (2007) Nucleic Acids Res. 35, D237-240 
16. Wood, H. E., Devine, K. M., and McConnell, D. J. (1990) Gene 96, 83-88 
17. Aggarwal, A. K., Rodgers, D. W., Drottar, M., Ptashne, M., and Harrison, S. C. (1988) Science 242, 899-
907 
18. Jordan, S. R., and Pabo, C. O. (1988) Science 242, 893-899 
19. Haas, W., Shepard, B. D., and Gilmore, M. S. (2002) Nature 415, 84-87 
20. Shi, K., Brown, C. K., Gu, Z.-Y., Kozlowicz, B. K., Dunny, G. M., Ohlendorf, D. H., and Earhart, C. A. 
(2005) Proc. Natl. Acad. Sci. U. S. A. 102, 18596-18601 
21. Casadaban, M. J., and Cohen, S. N. (1980) J. Mol. Biol. 138, 179-207 
22. Hanahan, D., Jessee, J., and Bloom, F. R. (1991) Methods Enzymol. 204, 63-113 
23. Miroux, B., and Walker, J. E. (1996) J. Mol. Biol. 260, 289-298 
24. Jacob, A. E., and Hobbs, S. J. (1974) J. Bacteriol. 117, 360-372 
25. Amann, E., Ochs, B., and Abel, K.-J. (1988) Gene 69, 301-315 
26. Poyart, C., and Trieu-Cuot, P. (1997) FEMS Microbiol. Lett. 156, 193-198 
27. Wirth, R., An, F. Y., and Clewell, D. B. (1986) J. Bacteriol. 165, 831-836 
28. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular cloning: a laboratory manual, 2nd Ed., 
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 
29. Shepard, B. D., and Gilmore, M. S. (1995) Methods Mol. Biol. 47, 217-226 
30. Manson, J. M., Keis, S., Smith, J. M., and Cook, G. M. (2003) Antimicrob. Agents. Chemother. 47, 204-
210 
31. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene 77, 51-59 
32. Gebhard, S., Tran, S. L., and Cook, G. M. (2006) Microbiology 152, 3453-3465 
33. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 
34. Laemmli, U. K. (1970) Nature 227, 680-685 
35. Higgins, D. E., and DiRita, V. J. (1996) J. Bacteriol. 178, 1080-1087 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
 12 
36. Cho, J. H., Ha, S. J., Kao, L. R., Megraw, T. L., and Chae, C.-B. (1998) Mol. Cell. Biol. 18, 5712-5723 
37. Meijer, W. J., Serna-Rico, A., and Salas, M. (2001) Mol. Microbiol. 39, 731-746 
38. Smith, H., Wiersma, K., Bron, S., and Venema, G. (1983) J. Bacteriol. 156, 101-108 
39. Küper, C., and Jung, K. (2005) J. Mol. Microbiol. Biotechnol. 10, 26-39 
40. Knol, J., Sjollema, K., and Poolman, B. (1998) Biochemistry 37, 16410-16415 
41. Rumpel, S., Razeto, A., Pillar, C. M., Vijayan, V., Taylor, A., Giller, K., Gilmore, M. S., Becker, S., and 
Zweckstetter, M. (2004) EMBO J. 23, 3632-3642 
 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
13 
LIST OF FIGURES 
 
FIGURE 1.  The effect of bacitracin concentration on the expression of bcrA-lacZ.  Cells of 
E. faecalis strains were grown to an OD600 of 0.5, challenged with varying concentrations of 
bacitracin for 1 h prior to harvesting and assayed for β-galactosidase activity, expressed in 
Miller units.  Results are shown as the mean of two biological replicates. A, strain 
AR01/DGVSpTCVA (BcrR+, BcrABD+).  B, strain JH2-2pAMbcr3pTCVA (BcrR+, BcrAB+).  
C, strain JH2-2pAMBcrRpTCVA (BcrR+, BcrAB-) 
 
FIGURE 2.  Physical map of bcrA-lacZ fusions used for promoter mapping studies.  E. 
faecalis strain AR01/DGVS was transformed with bcrA-lacZ fusion constructs and induction of 
bcrA-lacZ expression by bacitracin was studied.  The region of the bcrABD promoter contained 
within each construct is shown by a horizontal line with numbers given in bp relative to the 
bcrA start codon.  Cells were grown to an OD600 of 0.5 and challenged with 256 µg/ml 
bacitracin for 1 h prior to harvesting and assayed for β-galactosidase activity.  The mean β-
galactosidase activity for each construct is expressed in Miller units ± the standard error of the 
mean from three biological replicates. 
 
FIGURE 3.  Mutation of the inverted repeats within the bcrABD promoter.  E. faecalis 
strain AR01/DGVS was transformed with mutated bcrA-lacZ fusion constructs and induction of 
bcrA-lacZ expression by bacitracin was studied.  The location of inverted repeat sequences 
within the 69-bp region of the bcrA promoter as encoded in pTCVA are in boldface.  Also in 
boldface is the location of mutations made in these repeats.  Numbers given are in bp relative to 
the bcrA start codon.  Cells were grown to an OD600 of 0.5 and challenged with 256 µg/ml 
bacitracin for 1 h prior to harvesting and assayed for β-galactosidase activity.  The mean β-
galactosidase activity for each construct is expressed in Miller units ± the standard error of the 
mean from three biological replicates. 
 
FIGURE 4.  The bcrABD promoter.  A, region shown extends from -219 to +170 relative to 
the bcrA start codon, corresponding with the region encompassed by pTCVA.  The 69 bp 
sequence (-83 to -152) required for maximum bcrA-lacZ expression (Fig. 2) is shown in bold.  
The location and sequence of the direct repeat that constitutes the putative BcrR-binding sites 
(Fig. 3) are shown below their location in the wild-type sequence.  The putative -35, -10 
regulatory transcription elements, as determined by sequence homology, and the +1 
transcriptional start, as determined by 5´-RACE (Fig. 4b), are shown underlined.  The putative 
Shine-Dalgarno ribosome binding sequence, as determined by sequence homology, is boxed 
and the transcriptional start codon of bcrA and stop codon of bcrR are italicised.  Amino-acids 
encoded by bcrA and bcrR are denoted by a single letter below the sequence.  B, chromatogram 
obtained from sequencing the inverse cDNA strand obtained by 5´-RACE.  The box indicates 
three nucleotides, of which one is the transcriptional start site. 
 
FIGURE 5.  Expression, solubilization, purification and reconstitution of recombinant 
hexa-histidine tagged BcrR.  A, expression of BcrR in E. coli C41(DE3) inverted membrane 
vesicles.  Lanes 2-4 contain 20 µg of protein.  Lane 1, Protein molecular weight marker 
(Fermentas); lane 2, C41(DE3)pTrc99A vesicles; lane 3, C41(DE3)pTrcBcrR vesicles; lane 4, 
C41(DE3)pTrcBcrRHis vesicles.  B, solubilization of hexa-histidine tagged BcrR.  Lanes 2-6 
contain 20 µg of protein.  Lane 1, SeeBlue ladder (Invitrogen); lane 2, C41(DE3)pTrc99A 
vesicles; lane 3, C41(DE3)pTrcBcrRHis vesicles; lane 4, DDM-solubilized fraction; lane 5, 
DDM insoluble fraction; lane 6, sodium cholate-solubilized fraction.  C, purification of DDM-
solubilized protein fraction.  Lane 1, protein molecular weight marker; lane 2, pooled BcrRHis-
containing Ni2+-NTA affinity chromatography fractions (8 µg); lane 3, gel-filtration purified 
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14 
BcrRHis-containing fraction (4 µg).  D, reconstitution of gel-filtration purified BcrRHis into 
phosphatidylcholine liposomes.  Lane 1, pooled, concentrated BcrRHis-containing gel-filtration 
fractions (5 µg) before the reconstitution procedure; lane 2, 20 µl supernatant fraction after the 
reconstitution procedure; lane 3, BcrR-containing proteoliposomes (0.5 µl reconstituted 
fraction). 
 
FIGURE 6.  Electrophoretic mobility shift assays of BcrR-containing lipoposomes and 
probe DNA.  A, 1.2 ng of radioactively-labeled Bind1 (lanes 1-5), encompassing the putative 
BcrR-binding sites, or Bind2 (lanes 6-10), encompassing mutated BcrR binding sites, were 
incubated with different amounts of BcrR-containing liposomes (lanes 2-5 and 7-10) to give the 
following BcrR to DNA molar ratios;  lanes 2 and 7, 1000:1 (380 ng and 240 ng BcrR, 
respectively); lanes 3 and 8, 2000:1 (760 and 480 ng BcrR, respectively); lanes 4 and 9, 3000:1 
(1140 and 720 ng BcrR, respectively); lanes 5 and 10, 4000:1 (1520 and 960 ng BcrR, 
respectively).  B, 1.2 ng radioactively-labeled Bind1 was incubated with different amounts of 
BcrR-containing liposomes (lane 1, 0 ng; lane 2, 380 ng, lane 3, 760 ng, lanes 4-10, 1520 ng) 
and different amounts of competitive unlabeled bcrA116, encompassing 116 bp of the bcrA 
coding region (lane 5, 60 ng; lane 6, 120 ng), Bind1, encompassing the putative BcrR binding 
sites (lane 7, 60 ng; lane 8, 120 ng) and Bind2, encompassing BcrR binding sites mutated in 
regions R1 and R4 (lane 9, 95 ng; lane 10, 191 ng). 
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TABLE 1 
Bacterial strains and plasmids used in this study 
 
Strain or plasmid Description Reference or source 
E. faecalis   
AR01/DGVS AR01/DG cured of pJM02; Tcr, Bcr; bcrR+, bcrABD+ (3) 
AR01/DGVSpTCVA AR01/DGVS harboring pTCVA This study 
AR01/DGVSpTCVB AR01/DGVS harboring pTCVB This study 
AR01/DGVSpTCVC AR01/DGVS harboring pTCVC This study 
AR01/DGVSpTCVD AR01/DGVS harboring pTCVD This study 
AR01/DGVSpTCVE AR01/DGVS harboring pTCVE This study 
AR01/DGVSpTCVA1 AR01/DGVS harboring pTCVA1 This study 
AR01/DGVSpTCVA2 AR01/DGVS harboring pTCVA2 This study 
AR01/DGVSpTCVA3 AR01/DGVS harboring pTCVA3 This study 
AR01/DGVSpTCVA4 AR01/DGVS harboring pTCVA4 This study 
AR01/DGVSpTCVA1+3 AR01/DGVS harboring pTCVA1+3 This study 
AR01/DGVSpTCVA2+4 AR01/DGVS harboring pTCVA2+4 This study 
JH2-2 Type strain, RfR, FSR (24) 
JH2-2pAMBcrRpTCVA JH2-2 harboring pAMBcrR and pTCVA  This study 
JH2-2pAMBcrRHispTCVA JH2-2 harboring pAMBcrRHis and pTCVA This study 
JH2-2pAMbcr3pTCVA JH2-2 harboring pAMbcr3 and pTCVA This study 
   
E. coli   
MC1061 araD139, Δ(ara, leu)7697, ΔlacX74, galU-, galK-, hsr-, hsm+, strA (21) 
DH10B F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZ ΔM15 ΔlacX74 deoR recA1 araD139 Δ(ara leu)7697 
galU galK rpsL endA1 nupG (22) 
C41(DE3) Uncharacterized mutant derivative from BL21(DE3) (23) 
C41(DE3)pTrc99A C41(DE3) harboring expression vector pTrc99A This study 
C41(DE3)pTrcBcrR C41(DE3) harboring pTrcBcrR This study 
C41(DE3)pTrcBcrRHis C41(DE3) harboring pTrcBcrRHis This study 
   
Plasmids   
pAM401 E. coli-E. faecalis shuttle vector; CMR TCR  
pAMbcr1 pAM401 harboring 4.7 kb EcoRI fragment containing bcrR and bcrABD (3) 
pAMbcr3 pAM401 harboring 3.2-kb EcoRI-NdeI fragment from p2H7 containing bcrR, bcrA, and bcrB (3) 
pAMBcrR pAM401 harboring 1.28-kb PCR fragment containing bcrR This study 
pAMBcrRHis pAM401 harboring 1.28-kb PCR fragment containing bcrR with a C-terminal hexa-histidine tag This study 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
16 
pTCVlac E. coli-gram positive shuttle transcriptional fusion vector; Ermr, Kanr (26) 
pTrc99A E. coli expression vector; trc promoter, Ampr (25) 
pTCVA pTCVlac harboring 389 bp of bcrABD promoter region (position -219 to +170 relative to bcrA start 
codon) This study 
pTCVB pTCVlac harboring 321 bp of bcrABD promoter region (position -152 to +170 relative to bcrA start 
codon) This study 
pTCVC pTCVlac harboring 302 bp of bcrABD promoter region (position -133 to +170 relative to bcrA start 
codon) This study 
pTCVD pTCVlac harboring 280 bp of bcrABD promoter region (position -110 to +170 relative to bcrA start 
codon) This study 
pTCVE pTCVlac harboring 252 bp of bcrABD promoter region (position -83 to +170 relative to bcrA start 
codon) This study 
pTCVA1 pTCVA containing 3 bp substitution mutation (positions -135 to -133 relative to bcrA start codon) This study 
pTCVA2 pTCVA containing 4 bp substitution mutation (positions -123 to -120 relative to bcrA start codon) This study 
pTCVA3 pTCVA containing 3 bp substitution mutation (positions -103 to -101 relative to bcrA start codon) This study 
pTCVA4 pTCVA containing 3 bp substitution mutation (positions -91 to -88 relative to bcrA start codon) This study 
pTCVA1+3 pTCVA containing two 3 bp substitution mutations (positions -103 to -101 and -135 to -133 
relative to bcrA start codon) This study 
pTCVA2+4 pTCVA containing two 3 bp substitution mutations (positions -123 to -120 and  -91 to -88 relative 
to bcrA start codon) This study 
pTrcBcrR pTrc99A harboring bcrR This study 
pTrcBcrRHis pTrc99A harboring bcrR with a C-terminal hexa-histidine tag This study 
 
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
17 
TABLE 2 
Primers used for bcrA-lacZ transcriptional fusions 
Sequence used to introduce a restriction site is underlined, sequence used to introduce a mutation is in bold 
Name Sequence 5´-3´ Restriction site 
Used to create 
mutant construct 
EfbcrAP2F GTACTTCCCGGGTTGCTGTTAATCGGCAAGAT SmaI  
EfbcrAP2Eco
F GTACTTGAATTCTTGCTGTTAATCGGCAAGAT EcoRI 
 
EfbcrAP2R ATCCGTGGATCCAGCAAGCTGCAACATCATTT BamHI  
EfbcrAP3F TTGTGTCCCGGGTGTGACGGTAGGTTTCTTGG SmaI  
EfbcrAP5F GTCGGAGAATTCTTCATGCTGACATCTATTGT EcoRI  
EfbcrAP6F ATAGGCGAATTCACGATAAGTGTCGGAGCTTT EcoRI  
EfbcrAP7F AACATCGAATTCCCTTGAAAATAGGCTCTGAC EcoRI  
EfbcrAP7R CACATAGGATCCGCCAAGAAACCTACCGTCAC BamHI  
BcrAarea1/3F CATCTATTGAAAAAGCATTGTGACGGTAGGTTT  pTCVA4, pTCVA2+4 
BcrAarea1/3R CACAATGCTTTTTCAATAGATGTCAGCATGAAA  pTCVA4 
BcrAarea3F TTTTCATGCCCCCATCTATTGTGTCAGCATTG  pTCVA3 
BcrAarea3R CAATAGATGGGGGCATGAAAAAAGCTCCGACA  pTCVA3 
BcrAarea4F AATAGGCTCCCCCACGATAAGTGTCGGAGCTT  pTCVA1, pTCVA1+3 
BcrAarea4R CTTATCGTGGGGGAGCCTATTTTCAAGGTTTT  pTCVA1 
BcrAarea2/4F CACGATAAGAAAAGGAGCTTTTTTCATGCTGAC  pTCVA2 
BcrAarea2/4R AAAAGCTCCTTTTCTTATCGTGTCAGAGCCTAT  pTCVA2 
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